Half-year report · Q2
4893.TEDINET S100UJB3
Period2024-01-01 → 2024-06-30
Filed2024-10-15
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Amends S100U7Q7.
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Operating income | −¥682m | 2024-01-01 → 2024-06-30 | Standalone | Operating income |
| Operating income | −¥482m | 2023-01-01 → 2023-06-30 | Standalone | Operating income |
| Ordinary income | −¥682m | 2024-01-01 → 2024-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥832m | 2023-01-01 → 2023-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥682m | 2024-01-01 → 2024-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥832m | 2023-01-01 → 2023-06-30 | Standalone | Income before income taxes |
| Net income | −¥683m | 2024-01-01 → 2024-06-30 | Standalone | Profit loss |
| Net income | −¥1.1bn | 2023-01-01 → 2023-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥834m | 2023-01-01 → 2023-06-30 | Standalone | Profit loss |
| Total assets | ¥5.1bn | at 2024-06-30 | Standalone | Assets |
| Total assets | ¥5.8bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥6.1bn | at 2023-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥81m | at 2024-06-30 | Standalone | Liabilities |
| Total liabilities | ¥91m | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥5.0bn | at 2024-06-30 | Standalone | Net assets |
| Net assets / equity | ¥5.7bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥5.9bn | at 2023-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.9bn | at 2024-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.6bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥4.9bn | at 2024-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥5.6bn | at 2023-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥6.0bn | at 2023-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2022-12-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥611m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥873m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥509m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | ¥557,000 | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥5m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥3m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.9bn | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.9bn | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-15.79 | 2024-01-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-27.25 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-21.03 | 2023-01-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 98.3% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.3% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.6% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 43,301,765 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,276,765 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,202,865 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 354
| Item | Context | Value | Unit |
|---|---|---|---|
| Filing date cover page | FilingDateInstant | 2024-08-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第10期中（自2024年１月１日 至2024年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ノイルイミューン・バイオテック株式会社 | |
| Company name in english cover page | FilingDateInstant | Noile-Immune Biotech Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 玉田 耕治 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目12番10号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5843-7819 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役管理部長 永井 寛子 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目12番10号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5843-7819 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役管理部長 永井 寛子 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E38453 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 48930 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ノイルイミューン・バイオテック株式会社 | |
| Filer name in english | FilingDateInstant | Noile-Immune Biotech Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | false | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Current period end date | FilingDateInstant | 2024-06-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Comparative period end date | FilingDateInstant | 2023-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | true | |
| Identification of document subject to amendment | FilingDateInstant | S100U7Q7 | |
| Report amendment flag | FilingDateInstant | true | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Text · Plus | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |